India’s Hetero wins approval to sell COVID-19 drug favipiravir – ZAWYA

SourceZawya
SectorFinancial Markets
CountryUnited Arab Emirates

India's Hetero wins approval to sell COVID-19 drug favipiravir Favipiravir and another anti-viral treatment, remdesivir, have emerged as the most sought after medicines to treat COVID-19 in India    Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. BENGALURU - India's Hetero Labs Ltd has received regulatory approval to sell its version of anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Wednesday, as coronavirus infections in the world's third worst-hit nation crossed 1.5 million.The drug, priced at 59 rupees (79 cents) per tablet, is approved to treat mild to moderate COVID-19 and will...read more...